Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $1.74 Billion |
|---|---|
| Enterprise Value | $1.72 Billion |
| Annual dividend | $0.10 |
| Dividend yield | 0.65% |
| Earnings per Share | $0.24 |
| Beta | 1.59 |
| Outstanding Shares | 126,773,976 |
| P/E Ratio | 145.29 |
|---|---|
| PEG | -214.41 |
| Price to Sales | 6.88 |
| Price to Book Ratio | 6.88 |
| Enterprise Value to Revenue | 5.92 |
| Enterprise Value to EBIT | 8.59 |
| Enterprise Value to Net Income | 10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patie...